Skip to content
HowShorted

Viking Therapeutics, Inc. short interest in 2019

In 2019, Viking Therapeutics, Inc.'s disclosed short interest ran from 32.65% of shares outstanding on 15 Jan 2019 to 20.62% on 31 Dec 2019, a change of -12.03 percentage points. The year's high was 44.88% on 29 Mar 2019 and its low 20.62% on 31 Dec 2019, averaging 32.37% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.97 days on 15 Jul 2019. Full history: Viking Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Viking Therapeutics, Inc. in 2019

2019 in figures

Start of year
32.65% (15 Jan 2019)
End of year
20.62% (31 Dec 2019)
Change
-12.03 pp
High
44.88% (29 Mar 2019)
Low
20.62% (31 Dec 2019)
Average
32.37%
Highest days to cover
22.97 (15 Jul 2019)
SEC filings marked
8

Every report in 2019

Viking Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201932.65%9.03
31 Jan 201935.17%9.88
15 Feb 201936.73%7.97
28 Feb 201940.42%9.44
15 Mar 201940.02%9.7810-K filed, results (8-K)
29 Mar 201944.88%6.58
15 Apr 201940.23%6.37
30 Apr 201938.37%10.81
15 May 201937.05%12.5010-Q filed, results (8-K)
31 May 201935.53%17.10
14 Jun 201935.11%19.62
28 Jun 201932.06%14.57
15 Jul 201931.58%22.97
31 Jul 201927.47%14.78
15 Aug 201930.43%14.9210-Q filed, results (8-K)
30 Aug 201929.22%22.23
13 Sep 201932.60%18.19
30 Sep 201930.47%11.20
15 Oct 201928.59%19.36
31 Oct 201926.62%21.82
15 Nov 201926.36%11.3210-Q filed, results (8-K)
29 Nov 201922.73%9.28
13 Dec 201921.87%12.60
31 Dec 201920.62%13.37

See also: Viking Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.